Literature DB >> 8821529

Modulation of agonist-induced phosphoinositide metabolism, Ca2+ signalling and contraction of airway smooth muscle by cyclic AMP-dependent mechanisms.

B H Hoiting1, H Meurs, M Schuiling, R Kuipers, C R Elzinga, J Zaagsma.   

Abstract

1. The effects of increased cellular cyclic AMP levels induced by isoprenaline, forskolin and 8-bromoadenosine 3':5'-cyclic monophosphate (8-Br-cyclic AMP) on phosphoinositide metabolism and changes in intracellular Ca2+ elicited by methacholine and histamine were examined in bovine isolated tracheal smooth muscle (BTSM) cells. 2. Isoprenaline (pD2 (-log10 EC50) = 6.32 +/- 0.24) and forskolin (pD2 = 5.6 +/- 0.05) enhanced cyclic AMP levels in a concentration-dependent fashion in these cells, while methacholine (pD2 = 5.64 +/- 0.12) and histamine (pD2 = 4.90 +/- 0.04) caused a concentration-related increase in [3H]-inositol phosphates (IP) accumulation in the presence of 10 mM LiCl. 3. Preincubation of the cells (5 min, 37 degrees C) with isoprenaline (1 microM), forskolin (10 microM) and 8-Br-cyclic AMP (1 mM) did not affect the IP accumulation induced by methacholine, but significantly reduced the maximal IP production by histamine (1 mM). However, the effect of isoprenaline was small (15.0 +/- 0.6% inhibition) and insignificant at histamine concentrations between 0.1 and 100 microM. 4. Both methacholine and histamine induced a fast (max. in 0.5-2 s) and transient increase of intracellular Ca2+ concentration ([Ca2+]i) followed by a sustained phase lasting several minutes. EGTA (5 mM) attenuated the sustained phase, indicating that this phase depends on extracellular Ca2+. 5. Preincubation of the cells (5 min, 37 degrees C) with isoprenaline (1 microM), forskolin (10 microM) and 8-Br-cyclic AMP (1 microM) significantly attenuated both the Ca(2+)-transient and the sustained phase generated at equipotent IP producing concentrations of 1 microM methacholine and 100 microM histamine (approx. 40% of maximal methacholine-induced IP response), but did not affect changes in [Ca2+]i induced by 100 microM methacholine (95.2 +/- 3.5% of maximal methacholine-induced IP response). 6. Significant correlations were found between the isoprenaline-induced inhibition of BTSM contraction and inhibition of Ca2+ mobilization or influx induced by methacholine and histamine, that were similar for each contractile agonist. 7. These data indicate that (a) cyclic AMP-dependent inhibition of Ca2+ mobilization in BTSM cells is not primarily caused by attenuation of IP production, suggesting that cyclic AMP induced protein kinase A (PKA) activation is effective at a different level in the [Ca2+]i homeostasis, (b) that attenuation of intracellular Ca2+ concentration plays a major role in beta-adrenoceptor-mediated relaxation of methacholine- and histamine-induced airway smooth muscle contraction, and (c) that the relative resistance of the muscarinic agonist-induced contraction to beta-adrenoceptor agonists, especially at (supra) maximal contractile concentrations is largely determined by its higher potency in inducing intracellular Ca2+ changes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821529      PMCID: PMC1909321          DOI: 10.1111/j.1476-5381.1996.tb15207.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Beta-adrenoceptor stimulation inhibits histamine-stimulated inositol phospholipid hydrolysis in bovine tracheal smooth muscle.

Authors:  I P Hall; S J Hill
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

2.  The effects of isoproterenol on intracellular calcium concentration.

Authors:  Y Takuwa; N Takuwa; H Rasmussen
Journal:  J Biol Chem       Date:  1988-01-15       Impact factor: 5.157

3.  Effects of cAMP- and cGMP-dependent protein kinases, and calmodulin on Ca2+ uptake by highly purified sarcolemmal vesicles of vascular smooth muscle.

Authors:  E Suematsu; M Hirata; H Kuriyama
Journal:  Biochim Biophys Acta       Date:  1984-06-13

4.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

5.  Regulation of cytosolic calcium by cAMP and cGMP in freshly isolated smooth muscle cells from bovine trachea.

Authors:  J Felbel; B Trockur; T Ecker; W Landgraf; F Hofmann
Journal:  J Biol Chem       Date:  1988-11-15       Impact factor: 5.157

6.  Differential inhibitory effects of forskolin, isoproterenol, and dibutyryl cyclic adenosine monophosphate on phosphoinositide hydrolysis in canine tracheal smooth muscle.

Authors:  J M Madison; J K Brown
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

7.  In vivo functional antagonism between isoproterenol and bronchoconstrictants in the dog.

Authors:  J W Jenne; T K Shaughnessy; W S Druz; C J Manfredi; R E Vestal
Journal:  J Appl Physiol (1985)       Date:  1987-08

8.  A role for inositol 1,4,5-trisphosphate in the initiation of agonist-induced contractions of dog tracheal smooth muscle.

Authors:  T Hashimoto; M Hirata; Y Ito
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

9.  Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle.

Authors:  C A Jones; J M Madison; M Tom-Moy; J K Brown
Journal:  Am J Physiol       Date:  1987-07

10.  Differential inhibitory effect of isoproterenol on contractions of canine airways.

Authors:  J A Russell
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-09
View more
  9 in total

1.  Functional characterization of serum- and growth factor-induced phenotypic changes in intact bovine tracheal smooth muscle.

Authors:  Reinoud Gosens; Herman Meurs; Mechteld M Grootte Bromhaar; Sue McKay; S Adriaan Nelemans; Johan Zaagsma
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

2.  Muscarinic M(3) receptor-dependent regulation of airway smooth muscle contractile phenotype.

Authors:  Reinoud Gosens; Mechteld M Grootte Bromhaar; Annet Tonkes; Dedmer Schaafsma; Johan Zaagsma; S Adriaan Nelemans; Herman Meurs
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

3.  Epithelial Cells Induce a Cyclo-Oxygenase-1-Dependent Endogenous Reduction in Airway Smooth Muscle Contractile Phenotype.

Authors:  Michael J O'Sullivan; Elizabeth Gabriel; Alice Panariti; Chan Y Park; Gijs Ijpma; Jeffrey J Fredberg; Anne-Marie Lauzon; James G Martin
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

Review 4.  cAMP regulation of airway smooth muscle function.

Authors:  Charlotte K Billington; Oluwaseun O Ojo; Raymond B Penn; Satoru Ito
Journal:  Pulm Pharmacol Ther       Date:  2012-05-24       Impact factor: 3.410

Review 5.  Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+.

Authors:  Tim D Werry; Graeme F Wilkinson; Gary B Willars
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

Review 6.  Cyclic AMP in dendritic cells: A novel potential target for disease-modifying agents in asthma and other allergic disorders.

Authors:  Amy M Chinn; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-06-21       Impact factor: 8.739

7.  Airway smooth muscle relaxation results from a reduction in the frequency of Ca2+ oscillations induced by a cAMP-mediated inhibition of the IP3 receptor.

Authors:  Yan Bai; Michael J Sanderson
Journal:  Respir Res       Date:  2006-02-23

8.  The dopamine D1 receptor is expressed and facilitates relaxation in airway smooth muscle.

Authors:  Kentaro Mizuta; Yi Zhang; Dingbang Xu; Fumiko Mizuta; Frank D'Ovidio; Eiji Masaki; Charles W Emala
Journal:  Respir Res       Date:  2013-09-02

Review 9.  The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease.

Authors:  Philippa R Dale; Hana Cernecka; Martina Schmidt; Mark R Dowling; Steven J Charlton; Michael P Pieper; Martin C Michel
Journal:  Curr Opin Pharmacol       Date:  2014-03-27       Impact factor: 5.547

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.